Clinical Trial Update: Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of dabrafenib and trametinib for BRAF V600-mutant low-grade gliomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: University of California, San Francisco | Conditions: BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Status: RECRUITING